The Indianapolis pharma giant announced it will acquire Orna Therapeutics for $2.4 billion, putting Lily in the rat race to develop injectable, in vivo CAR-T therapies to eliminate the costly cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results